Format

Send to

Choose Destination
Pharmacol Res. 2015 Feb;92:18-22. doi: 10.1016/j.phrs.2014.08.002. Epub 2014 Sep 30.

Predicting post-vaccination autoimmunity: who might be at risk?

Author information

1
Department of Clinical Medicine and Rheumatology, Campus Bio-Medico University, Rome, Italy.
2
Department of Internal Medicine A, Shaare Zedek Medical Center, and the Hebrew University Medical School, Jerusalem, Israel. Electronic address: nesherg@szmc.org.il.
3
The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Sackler Faculty of Medicine, Incumbent of the Laura Schwarz-Kip Chair for Research of Autoimmune Diseases, Tel-Aviv University, Israel.

Abstract

Vaccinations have been used as an essential tool in the fight against infectious diseases, and succeeded in improving public health. However, adverse effects, including autoimmune conditions may occur following vaccinations (autoimmune/inflammatory syndrome induced by adjuvants--ASIA syndrome). It has been postulated that autoimmunity could be triggered or enhanced by the vaccine immunogen contents, as well as by adjuvants, which are used to increase the immune reaction to the immunogen. Fortunately, vaccination-related ASIA is uncommon. Yet, by defining individuals at risk we may further limit the number of individuals developing post-vaccination ASIA. In this perspective we defined four groups of individuals who might be susceptible to develop vaccination-induced ASIA: patients with prior post-vaccination autoimmune phenomena, patients with a medical history of autoimmunity, patients with a history of allergic reactions, and individuals who are prone to develop autoimmunity (having a family history of autoimmune diseases; asymptomatic carriers of autoantibodies; carrying certain genetic profiles, etc.).

KEYWORDS:

Adjuvants; Allergy; Autoantibodies; Autoimmunity; Vaccine

PMID:
25277820
DOI:
10.1016/j.phrs.2014.08.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center